Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients
Abstract Tacrolimus is an important immunosuppressant used in the treatment of myasthenia gravis (MG). However, the population pharmacokinetic (PK) characteristics together with the exposure‐response of tacrolimus in the treatment of MG remain largely unknown. In this study, we aimed to develop a po...
Saved in:
Main Authors: | Di Chen (Author), Qingyu Yao (Author), Wenjun Chen (Author), Jian Yin (Author), Shifang Hou (Author), Xiaoxin Tian (Author), Ming Zhao (Author), Hua Zhang (Author), Liping Yang (Author), Tianyan Zhou (Author), Pengfei Jin (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis
by: Courtney Townsel, et al.
Published: (2016) -
Physiotherapy in myasthenia gravis
by: Klaudia Kwiatkowska, et al.
Published: (2018) -
Physiotherapy in myasthenia gravis
by: Klaudia Kwiatkowska, et al.
Published: (2018) -
Juvenile myasthenia gravis
by: Prastiya I. Gunawan, et al.
Published: (2007) -
Prognosis of Myasthenia Gravis
by: J Gordon Millichap
Published: (1992)